Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.
Maximum standard uptake value of 18F-fluorodeoxyglucose positron emission tomography is a prognostic factor for progression-free survival of newly diagnosed patients with diffuse large B cell lymphoma.
复制标题
18F-氟脱氧葡萄糖正电子发射断层扫描的最大标准摄取值是新诊断的弥漫性大B细胞淋巴瘤患者无进展生存的预后因素。
DOI：
10.1007/s00277-012-1602-3
复制
发表时间：
2013-01
影响因子：
3.5
通讯作者：
Hara, Masamichi
中科院分区：
文献类型：
--
作者：
Miyazaki, Yukihiro;Nawa, Yuichiro;Miyagawa, Masao;Kohashi, Sumiko;Nakase, Koichi;Yasukawa, Masaki;Hara, Masamichi
一种快速确定预后的方法将大大促进弥漫性大 B 细胞淋巴瘤 (DLBCL) 患者的治疗，这种方法比细胞学或特异性病理检查更容易、更早进行。有人建议，与 SUVmax 高的患者相比，18F-氟脱氧葡萄糖正电子发射断层扫描 (FDG-PET) 最大标准摄取值 (SUVmax) 较低的新诊断 DLBCL 患者更有可能获得成功治疗并保持缓解，但这一概念的研究很少。我们回顾性分析了 50 名新发 DLBCL 患者，以评估 SUVmax 与疾病进展之间的关系。对于低 SUVmax (n = 10) 和高 SUVmax (n = 40) (P = 0.255) 的患者，3 年总生存率分别为 90 和 72%，无进展生存 (PFS) 率分别为 90 和 39% (P = 0.012)。通过多变量分析，修订后的国际预后指数 (R-IPI) 和诊断时的 SUVmax 显示可预测更长的 PFS。通过 R-IPI 分类为预后良好组的低 SUVmax 患者的 3 年 PFS 为 100%，而高 SUVmax 患者的 3 年 PFS 为 62%（P = 0.161）；通过 R-IPI 分类为预后不良组的低 SUVmax 患者的 3 年 PFS 为 80%，高 SUVmax 患者的 3 年 PFS 为 18%（P = 0.050）。我们的结论是，对于新诊断的 DLBCL 患者，FDG-PET 的 SUVmax 是疾病进展的重要预测因子，特别是对于 R-IPI 预后不良的患者。
The treatment of patients with diffuse large B cell lymphoma (DLBCL) would be greatly facilitated with a rapid method for determining prognosis that can be performed more easily and earlier than cytological or specific pathological examinations. It has been suggested that newly diagnosed patients with DLBCL who have low maximum standard uptake value (SUVmax) on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) are more likely to be successfully treated and remain in remission compared with patients with high SUVmax, but this concept has been poorly studied. We retrospectively analyzed 50 patients with de novo DLBCL to evaluate the relationship between the SUVmax and disease progression. For patients with low SUVmax (n = 10) and high SUVmax (n = 40) (P = 0.255), respectively, the 3-year overall survival rates were 90 and 72 %, and the progression-free survival (PFS) rates were 90 and 39 % (P = 0.012). By multivariate analysis, the revised International Prognostics Index (R-IPI) and SUVmax at diagnosis were shown to predict longer PFS. The 3-year PFS for patients with low SUVmax classified into the good prognosis group by R-IPI was 100 vs. 62 % for those with high SUVmax (P = 0.161), and patients with low SUVmax classified into the poor prognosis group by R-IPI was 80 vs. 18 % for those with high SUVmax (P = 0.050). We conclude that the SUVmax on FDG-PET for newly diagnosed patients with DLBCL is an important predictor of disease progression, especially for patients with poor prognosis by R-IPI.
登录
查看更多内容
影响因子：
51.1
作者：
Pfreundschuh, Michael;Schubert, Joerg;Loeffler, Markus
通讯作者：
Loeffler, Markus
影响因子：
20.3
作者：
Kobe, Carsten;Dietlein, Markus;Engert, Andreas
通讯作者：
Engert, Andreas
影响因子：
2.6
作者：
Watanabe, Reina;Tomita, Naoto;Ishigatsubo, Yoshiaki
通讯作者：
Ishigatsubo, Yoshiaki
影响因子：
45.3
作者：
Haioun, C;Lepage, E;Reyes, F
通讯作者：
Reyes, F
影响因子：
20.3
作者：
Yamaguchi, M;Seto, M;Nakamura, S
通讯作者：
Nakamura, S